Navigation Links
Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
Date:7/18/2011

m infection of the inner lining of the colon by C. difficile bacteria, which produce toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death. Patients typically develop CDAD from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, possibly allowing C. difficile bacteria to flourish. Older patients in particular are at risk for CDAD, potentially because of a weakened immune system or the presence of underlying disease. Approximately two-thirds of CDAD patients are 65 years of age or older.

Current estimates suggest CDAD may affect more than 700,000 people in the U.S. each year, though the incidence may be higher as many cases are believed to be undiagnosed, untreated and underreported. The disease adds significant costs and burden to the U.S. healthcare system with estimates for medical treatment and hospital stays associated with CDAD reaching as much as $3.8 billion every year. Historically, approximately 20% to 30% of CDAD patients who initially respond to treatment experience a clinical recurrence.

About DIFICID™ (fidaxomicin) Tablets

DIFICID is the first antibacterial drug indicated for CDAD to be approved in more than 25 years. It is indicated for the treatment of CDAD in adults 18 years of age or older. DIFICID is administered in 200 mg tablets given orally twice daily. In two large Phase 3 clinical studies DIFICID had a clinical response rate at the end of the 10-day treatment period that was non-inferior to oral vancomycin. DIFICID demonstrated superior sustained clinical response, defined as clinical response at the end of treatment and survival without proven or suspected CDAD recurrence through 25 days beyond the end of treatment, compared to oral vancomycin. This difference was due to lower rates of proven or suspected CDAD during the follow-up period in DIFICID-treated patients. Similar rates of clinical respo
'/>"/>

SOURCE Optimer
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2. Optimer Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
3. Optimer Pharmaceuticals Reports First Quarter 2011 Financial Results
4. Optimer Pharmaceuticals Expands Senior Management Team
5. Optimer Pharmaceuticals to Present at May 2011 Investor Conferences
6. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
7. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
8. Trading Halted Today in Optimer Pharmaceuticals Stock
9. Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients
10. Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality
11. Optimer Pharmaceuticals Announces Issuance of Key Patent Covering Fidaxomicin Methods of Use as a Treatment of Clostridium difficile infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... CHESTERBROOK, Pa. , May 24, 2013  Auxilium ... that executive management will participate in the Deutsche Bank ... the Westin Boston Waterfront Hotel.  Mr. Adrian ... scheduled to present an overview of the Company and ... May 29, 2013.   (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ...
(Date:5/24/2013)... BEIJING , May 24, 2013  Sinovac ... leading provider of biopharmaceutical products in ... main operating subsidiary company of Sinovac, obtained the ... (GMP Certificate) from the China State and Food ... district bulk production plants, and its Changping filing ...
(Date:5/24/2013)... England and BOSTON , May 24, ... discovery and development company, is pleased to announce that it has ... to augment the Company,s business development capabilities in Japan ... more than 15 years of experience in business development, licensing and ... Sciences, Inc., Roche Pharma ( Japan ), Nippon Roche ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 4Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 2Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 3Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2
... MERCER ISLAND, Wash., Dec. 22, 2010 Renal Advantage and ... the third largest provider of dialysis services in the U.S., ... – terms of which were not disclosed – was completed ... serving more than 19,000 patients in 260 locations in 32 ...
... AstraZeneca (NYSE: AZN ... will discontinue the development of CERTRIAD™ (rosuvastatin calcium and fenofibric ... dyslipidemia. This means the co-development and license agreement with Abbott ... Complete Response Letter (CRL) for the CERTRIAD New Drug Application ...
Cached Medicine Technology:Renal Advantage and Liberty Dialysis Deal Completed 2Renal Advantage and Liberty Dialysis Deal Completed 3
(Date:5/25/2013)... (PRWEB) May 25, 2013 Actos ... underway in U.S. District Court, Western District of Louisiana, ... According to a Case Management Order issued on May ... filing of contested motions in the Actos bladder cancer ... (In re: Actos Product Liability Litigation, MDL No. 2299) ...
(Date:5/25/2013)... great companions for senior citizens, but elderly people who always ... likely to crash than those who never drive with a ... licensed drivers aged 70 and older. The nearly 700 participants ... their pet in the car. Among those who always ... high as among those who never drove with their pet. ...
(Date:5/25/2013)... May 25, 2013 Radius Engineering ... shelter company in the US and has been ... for over 35 years. M.E. and President, Walton ... of NBC Weapon Fundamentals and Shelter Engineering Standards, ... bible on shelter engineering. McCarthy is considered the ...
(Date:5/25/2013)... 2013 Providing patients with their best weight ... of weight management professionals. But, aside from educating patients on ... Doc’s hCG diets also provide patients, who have ... like bullying, more control over their lives by achieving their ... the underlying factors of weight gain derived from earlier abuse, ...
(Date:5/25/2013)... New York, NY (PRWEB) May 25, 2013 ... reported that many people do not wish to discuss or ... responsibility in life. FuneralFinancials.com released a Must-Do ... , 1. Funeral Financials recommends, “Creating a personal fact ... be used to organize financial information and personal data. ...
Breaking Medicine News(10 mins):Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Seniors More Likely to Crash When Driving With Pet: Study 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 3Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 3Health News:FuneralFinancials.com Releases Last Wishes Must-Do List 2
... to the heart improves as one watches more comedy films, ... Researchers asked 20 healthy young adults to watch 15 to ... of 48 hours apart. // ,Participants were ... or taking aerobic exercise the evening before the experiment, as ...
... can be detected through measuring a certain protein present in ... reported to be the fifth most malignant, which recorded 63,210 ... 13,000 deaths. The country has a total of 500,000 patients ... recurrence is between 50% and 90%. ,There ...
... US health insurers who are under contract with the new ... Administration to be in a position to make 30 day ... as several patients // across the country were reportedly unable ... the responsibility of insurers to ensure that an amount of ...
... very upset and has sent a letter to the acting head ... his letter he had asked the FDA to provide a full ... was reveled that the tainted tissues were used for the patients ... probe into the matter about the case of the Brooklyn funeral ...
... Bird flu pandemic is on the rise as there are ... Haemagglutinin antigen fragment of the bird flu virus and there ... by these viruses. Scientists are working out plans of Passive ... of the infected bird flu patient, the antibody is produced ...
... plague has hit Western Australia's south region with 50 cases ... River virus has also been // reported in the Territories ... days. ,Entomologist Nina Kurucz said that the pre-monsoon ... "The problem is that this sort of mosquito can fly ...
Cached Medicine News:
Highly concentrated daily cleaner with Microclens beads for superior cleaning action....
Round knurled handle. Overall length 130 mm....
... contact lens cleaning solution is ... and professionally proven cleaner. A ... resulting in a very effective ... cosmetic residue, salts, mucous and ...
Optimum C/D/S Solution is a sterile cleaning, disinfecting, and storage solution for use with fluorosilicone acrylate and silicone acrylate rigid gas permeable (RGP) and hard contact lenses....
Medicine Products: